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Abstract
Background HIV-associated neurocognitive disorders
(HAND) has been associated with the up-regulation of
various oxidative stress pathways. Previous studies have
linked the neuronal damage observed in individuals
diagnosed with HAND to increased nitrotyrosine modifi-
cation of neuronal proteins.
Materials and methods Tyrosine nitration alters protein
structure and function, affects biological half-life, and poten-
tially prevents the phosphorylation of key tyrosine residues
involved in signal transduction pathways. Therefore, in this
study we employed proteomics-based experimental
approaches to investigate nitrotyrosine-modified proteins in
pooled cerebrospinal fluid (CSF) of individuals diagnosedwith
HAND. To identify specific nitrotyrosine-modified proteins in
the CSF of individuals diagnosed with HAND, affinity
purification and high-performance tandem mass spectrometry
are utilized in a “bottom-up” proteomics approach.
Results From tandem mass spectrometric analysis, we
identified major proteins that underwent nitration as a result
of nitro-oxidative stress in the CSF of individuals diag-
nosed with HAND. We also utilized analytical and
biochemical techniques to characterize the expression and
modification site of in vivo nitrated lipocalin-type
prostaglandin-D synthase in HAND CSF.
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BSA Bovine Serum Albumin
CSF Cerebrospinal fluid
HIV Human Immunodeficiency Virus
HAND HIV-associated neurocognitive disorders




During the initial phases of human immunodeficiency virus
(HIV) infection, the virus penetrates the blood-brain barrier
and invades the host central nervous system (CNS). This
leads to a cascade of intracellular anti-viral events including
the production of oxidative stress that facilitate the control
of viral replication and production [1]. The over production
of these anti-viral responses have been linked to various
neurological complications due to neuronal damage and
toxicity, such as HIV-associated neurocognitive disorders
(HAND) [1, 2]. However, with the advent of highly active
antiretroviral therapy (HAART) the incidence and severity
of HAND has drastically decreased but the prevalence of
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HAND has increased [3]. HAART has reduced the viral
load, significantly improved the CD4+ T-cell counts, and
extended the life expectancy of individuals infected with
HIV. Consequently, the life expectancy benefits associated
with HAART and the low turnover of HIV-infected cells in
the CNS has led to the progressive rise in milder HIV-
associated cognitive disorders. Little is known about the
mechanisms and pathways associated with the development
and progression of HAND; therefore, current diagnosis of
HAND requires extensive neuropsychological testing.
Although the mechanism of development of HAND is
unknown, previous studies of individuals diagnosed with
HAND have shown a correlation between the degree of
severity of HAND and elevated levels of inducible nitric
oxide synthase (iNOS) [4]. The enzymatic activity of iNOS
leads to the production of nitric oxide (NO), which can act
as a cytotoxic effector molecule or a pathogenic mediator
when produced at high rates [5]. Elevated levels of free
reactive nitrogen species interact with neuronal proteins and
lead to the selective nitration of tyrosine residues. Protein
tyrosine nitration is a dynamic and selective post-
translational modification that is a well-established bio-
marker of oxidative stress. Nitrotyrosine is the product of
the uncatalyzed reaction of a tyrosine residue and perox-
ynitrite (ONOOˉ), which is a powerful oxidant produced
from the reaction of NO and superoxide (Fig. 1). In
addition to the uncatalyzed reaction, catalyzed reactions of
ONOOˉ with CO2, transition metals, and myeloperoxidase
can also lead to the formation of nitrotyrosine [6]. Tyrosine
nitration alters protein structure and function, affects
biological half-life, solubility, and increases the degree of
protein degradation [5]. The addition of the bulky –NO2
group also imposes steric restrictions on the tyrosine
aromatic ring which can lead to the inhibition of phosphor-
ylation of the phenolic hydroxyl group of the phenolic ring
of tyrosine [6]. Therefore, characterization of nitrotyrosine-
modified proteins in cerebrospinal fluid (CSF) offers unique
opportunity for the identification of key proteins that contrib-
ute to the HIV-induced effects of neurological dysfunction.
In this study, we employ affinity-based purification and
high-performance tandem mass spectrometry in a “bottom-
up” proteomics approach to investigate nitrotyrosine-
modified proteins in the CSF of individuals diagnosed with
HAND.
Materials and Methods
In vitro nitration of BSA and L-PGDS One milligram of
bovine serum albumin (BSA; Sigma, St. Louis, MO; and
Sigma) was incubated with a 1.54 mM (100 µL) solution of
peroxynitrite (Upstate, Lake Placid, NY) in 0.3 M NaOH
for 45 min at room temperature. Following nitration, the
peroxynitrite-treated BSA (n-BSA) solution was desalted
with protein desalting spin columns (Pierce, Rockford, IL).
High-Performance Liquid Chromatography Analysis The
desalting spin column flowthrough fraction was used to
validate in vitro peroxynitrite-treated BSA. One hundred
microliters of n-BSA (100 µg) in 0.1% trifluoroacetic acid
(TFA) was injected onto a 250×2.0 mm Jupiter 5 µ C4
300A (Phenomenex, Torrance, CA) reversed-phase column.
The aqueous mobile phase A consisted of 0.1% TFA in
water (Solvent A) and the organic mobile phase consisted
of 0.1% TFA in ACN (Solvent B). The nitrated and non-
nitrated protein was eluted with the following gradient:
30% Solvent B at 0–5 min, 50% Solvent B at 35 min,
100% Solvent B at 40 min, and 3% Solvent B at 50 min.
The absorbance was monitored at both 214 and 350 nm.
CSF Specimens The human CSF samples were obtained
from non-HIV-infected and HAND diagnosed individuals
from the Lumbar Puncture Clinic at Johns Hopkins
Hospital. The samples were divided into two groups: non-
HIV (n=3) and HAND (n=4). The non-HIV group
consisted of two patients with normal pressure hydroceph-
alus and one with possible multiple sclerosis. None of them
had any risk factors for HIV infection. The collected CSF
samples were centrifuged at 3,000 rpm for 10 min to
remove cellular debris. The cell-free CSF supernatant was
stored at −80°C in 1.0 mL aliquots until further analysis to
prevent sample degradation. Prior to analysis, the CSF
samples were heated at 60°C for 20 min and pooled.
Pooling of CSF was necessary since the detailed proteomic
analysis required large amounts of CSF. CSF samples from
ten individuals were initially screened for nitrotyrosine by
slot blot as previously described [7] and the four HAND











Immonium Ion:       136.10
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Fig. 1 Tyrosine nitration pathway
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content were pooled for further analysis. This optimized our
chances for detection of nitrotyrosine-modified proteins.
Nitrotyrosine Enrichment Prior to affinity purification of
the nitrotyrosine-modified proteins, the control and dis-
eased (HAND) CSF were immunodepleted with the
Proteoseek™ antibody-based albumin/IgG removal kit
(Pierce, Rockford, IL). Following immunodepletion, the
CSF samples were incubated with 100 µg of anti-
nitrotyrosine (clone 1A6) agarose conjugate (Upstate, Lake
Placid, NY) overnight at 4°C with gentle agitation to
maintain optimal distribution of the antibody resin in the
protein mixture. The resin was collected by centrifugation
at 1,500×g for 1 min and washed twice with phosphate
buffer saline (PBS, pH 7.4). The nitrated proteins were
eluted with 5% (v/v) formic acid in water and the fractions
were concentrated in a speedvac.
Lipocalin-type Prostaglandin D Synthase Enrichment
Co-immunoprecipitation of lipocalin-type prostaglandin D
synthase (L-PGDS) was performed according to the Catch
and Release v2.0 kit (Upstate, Lake Placid, NY) recommenda-
tions. The pooled albumin/IgG depleted CSF samples were
incubated with the anti-LPGDSmonoclonal antibody (Cayman
Chemical, Ann Arbor, MI) at 4°C overnight. Following
incubation, the spin column was washed twice with 1× wash
buffer and each wash was centrifuged at 5,000 rpm for 1 min.
The antigen:antibody complex was eluted from the affinity
resin with non-denaturing elution buffer (PBS, pH7.4) and the
affinity purification fractions were concentrated in the speedvac
and resuspended in 50 µL of PBS (pH7.4). The above
procedure was utilized to enrich the nitrotyrosine-modified
protein from the LPGDS-enriched CSF samples.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
The immunoprecipitation fractions were loaded and separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) on a NuPAGE 4-12% (w/v) Bis-Tris gel
(Invitrogen, Carlsbad, CA) and visualized via silver staining


























In vitro n-BSA(214 nm)
In vitro n-BSA(350nm)
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Fig. 2 Reversed-phase LC analysis of in vitro n-BSA containing unmodified Angiotensin II (internal non-nitrated standard) at 214 and 350 nm



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Clin Proteom (2010) 6:29–41 33
5% (v/v) acetic acid in water for a minimum of 30 min,
followed by a second fixation step in 50% EtOH for 10 min.
The gels were then washed twice for 10 min in water to
remove the remaining acid. Prior to staining, the gels were
sensitized for 2 min using an aqueous solution of 0.02% (w/v)
sodium thiosulfate followed by three washes for 5 min each
with water to remove the excess sodium thiosulfate. After
rinsing, the gels were incubated for 30 min with gentle
agitation in chilled 0.1% (w/v) silver nitrate. Following staining
with silver nitrate, the gels were developed in 2% (w/v) sodium
carbonate containing 0.037% (v/v) formaldehyde in water. The
staining reaction was quenched with an aqueous solution of
5% (v/v) acetic acid for 5 min. The gels were stored at 4°C in
1% acetic acid in water until further analysis.
Immunoblot Analysis The nitrotyrosine and L-PGDS immu-
noprecipitation elution fractions were separated by SDS-
PAGE on a NuPAGE 4–12% Bis-Tris gel (Invitrogen,
Carlsbad, CA). The proteins were then transferred to a
polyvinylidene fluoride membrane using the iBlot™ Gel
Transfer Device (Invitrogen, Carlsbad, CA) and the SNAP
i.d.™ protein detection system (Millipore, Billerica, MA) was
used to conduct the immunoblot. The primary antibodies used
were mouse monoclonal anti-nitrotyrosine (2 µg/mL; Upstate,
Lake Placid, NY) and rat monoclonal anti-L-PGDS (2 µg/mL;
CaymanChemical, AnnArbor, MI). The respective secondary
antibodies (1:5,000 dilution) were goat anti-mouse IgG
IRDye® 680 nm (LI-COR Biosciences, Lincoln, NE) and
goat anti-rat IgG IRDye® 680 nm (LI-COR Biosciences). The
fluorescent blots were imaged on the Odyssey infrared
imaging system (LI-COR Biosciences).
In-gel Trypsin Digestion Stained protein bands were ex-
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A) Normalized Ion Chromatograms
[M+3H]+3
[M+3H]+3
B) Tyrosine and Nitrotyrosine Immonium Ion Detection ([M+3H]+3 175- 190)
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C) Tandem MS of in vitro -BSA Peptide









































































































































































Fig. 3 LTQ-Orbitrap analysis of in vitro n-BSA tryptic peptides:
RHPEYAVSVLLR and RHPEYNO2AVSVLLR. The base peak ion
chromatograms of the MS analysis of the tryptic digestion of in vitro
n-BSA are presented in Panel A. The single ion chromatograms at m/z
480.61 and m/z 495.60 represent the detection of the [M+3H]+3 ion of
the non-nitrated and nitrated BSA peptide, respectively. The tandem
MS spectra of m/z 480.61 and m/z 495.60 are in Panel C. In addition
to changing the peptide mass, the –NO2 group also increases the
Tyrosine immonium ion from m/z 136.10 to m/z 181.06 (Panel B)
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mixture of 30 mM potassium ferricyanide: 100 mM sodium
thiosulfate) for 10 min. at room temperature. The gel bands
were washed with 100 mM ammonium bicarbonate
(NH4HCO3) and dehydrated with ACN. After drying the
bands in the speedvac, pre-selected gel bands were
rehydrated in a trypsin solution (10 ng of trypsin in
50 mM NH4HCO3) on ice for 45 min. The supernatant
was removed and 100 µL of 50 mM NH4HCO3 was added
to the bands and the bands were placed at 37°C overnight
for digestion. The supernatants were removed and the
remaining peptides were extracted with 50 µL of 1:1
mixture of ACN and 5% formic acid in water. Following
extraction, the peptides were dried in a speedvac and re-
suspended in 20 µL of LC-MS loading buffer (3% ACN/
0.1% formic acid in H2O) for tandem MS analysis.
NanoLC LTQ-Orbitrap hybrid MS The peptide mixtures
were separated by on-line reversed-phase (RP) nanoscale
capillary liquid chromatography (nano-LC) and analyzed
by ESI-tandem MS (LTQ-Orbitrap, Thermo Fisher Scien-
tific, Berman, Germany). Prior to injection onto the
reversed-phase column, the sample was injected onto a
10 µL injection loop using the Agilent 1200 nanoflow
autosampler (Agilent Technologies, Palo Alto, CA). From
the injection loop, the sample was flushed onto the in-house
packed fused-silica trap column at a flowrate of 5 µL/min
to remove salt and particulate from the peptide mixture.
After five washes, the 10-port valve switched from offline
to inline with the mobile phase gradient.
For peptide separation, the peptide mixture was injected
onto the 12 cm reversed-phase, fused-silica capillary
column (ID: 75 µm, packed in-house with C18 5 µm
packing material, YMC Europe GmbH) using the Eksigent
nanoLC-2D system (Eksigent, Dublin, CA). The aqueous
mobile phase consisted of 0.1% formic acid in H2O
(Solvent A) and the organic mobile phase consisted of
0.1% formic acid in ACN (Solvent B). The peptides were
eluted from the hydrophobic stationary phase with a linear
gradient and the total gradient time was 90 min. Solvent B





































































































C) Total L-PGDS Total NO2-Modified L-PGDS
Total NO2-Modified CSF Protein
IP: L-PGDS
Slot Blot:













IP : Nitrotyrosine Western Blot: 1 Ab: Anti-Nitrotyrosine(monoclonal)





















Fig. 4 1-D electrophoresis (a) of nitrotyrosine enrichment fractions
from pooled non-HIV (control) and HAND CSF. Lane 1, MW marker;
lane 2, flowthrough (non-nitrated proteins); lane 3, pre-elution PBS
wash; and lane 4, 5% formic acid elution (enriched nitrated proteins).
The total number of spectra acquired (normalized spectrum count)
from Non-HIV (control) and HAND CSF nitrotyrosine-modified sub-
proteome (a). Quantitative immunoblot analysis of nitrotyrosine
content in albumin/IgG-depleted non-HIV (control) and HAND
(diseased) CSF (b) and L-PGDS (c) determined by slot blot analysis
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and to 20% in 5 min, followed by an increase to 60% at
60 min. At 80 min, Solvent B was increased to 97% and
held constant for 2 min and ramped down to 3% at 85 min
to re-equilibrate the reversed-phase column. The eluted
peptides were directly transferred from the capillary column to
a laser-pulled electrospray ionization emitter tip (New
Objective, Woburn, MA) at a spray voltage of 2.0 kV. Data-
dependent acquisition was performed on the LTQ-Orbitrap
(Thermo Fisher Scientific) mass spectrometer in the positive-
ion mode. The survey full MS scans (m/z 200–2,000) were
acquired in the Orbitrap mass analyzer with a resolution of
R=15,000. The four most intense ions from the full MS scan
were fragmented with collision-induced dissociation (CID)
fragmentation and the MS/MS scans (m/z 100–2,000) were
also acquired in the Orbitrap with a resolution of R=7,500.
The fragmented target ions were dynamically excluded for
90 s. General mass spectrometric conditions were as follows:
no sheath and auxiliary gas; ion transfer tube temperature of
200°C; collision gas pressure was 1.5 mTorr; normalized
collision energy was 35.0%; ion selection threshold was
10,000; the activation q-value was 0.25; and the activation
time was 30 ms.
Database Search and Data Analysis The tandem mass
spectra were extracted and the charge state deconvoluted by
Mascot Distiller (v. 2.0, Matrix Science). De-isotoping was
not performed. The MS/MS samples were analyzed using
MASCOT (Matrix Science (version 2.2), London, UK) and
X! Tandem (www.thegpm.org; version 2007.01.01.1). The
IPI_Human_20060712 protein database (selected for Homo
sapiens, version 3.49, 60397 entries) was used by both
MASCOT and X! Tandem to search the tandem MS data.
For Orbitrap data, a 0.1 Da mass tolerance was allowed for
parent ion masses and a 0.5 Da mass tolerance was used for
Table 2 Relative quantification of nitrotyrosine-modified proteins from non-HIV and HAND CSF
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the product ions that were created via CID fragmentation.
Two variable modifications were used for both MASCOT
and X! Tandem: oxidation of methionine and nitration of
tyrosine. The results from MASCOT and X! Tandem were
uploaded onto the Scaffold Proteome software (Proteome
Software Inc., Portland, OR) to formulate a final protein
list. Scaffold Proteome software employs PeptideProphet
and ProteinProphet algorithms to generate a bimodal
histogram of the correct and incorrect identifications. The
algorithms use the histogram to estimate the degree of
overlap to determine the probability cutoff for correct
peptide identifications. The Scaffold Proteome data sets
were annotated and analyzed using ProteinCenter (Proxeon
Biosystems, Odense Denmark).
Results
In vitro Nitrotyrosine Results: In vitro n-BSA Model To
validate the affinity enrichment of in vitro nitrotyrosine-
modified BSA, the antibody-enriched n-BSA was analyzed
via reversed-phase HPLC (RP-HPLC). The RP-HPLC
chromatogram in Fig. 2 displays a peak representative of
in vitro n-BSA at 214 and 350 nm. Unmodified angiotensin
II was added as an internal standard and the angiotensin II
peak was present only in the 214 nm chromatogram. The
presence of in vitro n-BSA at both 214 and 350 nm
validates in vitro nitration and affinity enrichment because
the peptide bond absorbs at 214 nm and the –NO2 group
attached to the tyrosine residue(s) absorbs at 350 nm. The
absorbance of unmodified tyrosine is 274 nm; however, the
presence of the –NO2 group alters the physical and
chemical properties of the tyrosine residue, leading to a
shift in UV absorption of tyrosine. Absorption of nitrated
tyrosine is pH-dependent, at acidic pH the prominent band
of free nitrotyrosine was found to be at 350 nm, which
represents the neutral form of nitrotyrosine [10, 11].
However, at basic pH the major band of free nitrotyrosine
was found to be at 422 nm, which represents the ionized
form of nitrotyrosine (Fig. 2 Inset) [10, 11]. Following RP-
HPLC analysis, the co-immunoprecipitation fractions were
digested and analyzed by tandem MS via LTQ-Orbitrap.
The peptides identified from tryptic digestion of in vitro n-
BSA are summarized in Table 1, however, few nitrated
peptides were observed in the analysis. This may be due to
the differential nitration of tyrosine residues on BSA
proteins and/or ion suppression during MS/MS analysis.
The non-nitrated and nitrated RHPEYAVSVLLR ions were
detected in the in vitro n-BSA digest (Fig. 3a–c). The
detection of both the nitrated and non-nitrated forms of the
peptide may stem from the differential nitration of the BSA
protein. From the total (normalized) ion chromatogram, the
triply charged ion for the non-nitrated (m/z 480.61) and
nitrated (m/z 495.60) form of RHPEYAVSVLLR are
present in the selected ion chromatograms (Fig. 3a). Due
to the attachment of the –NO2 group on Tyr
364, the peptides
Table 3 Identified peptides from tryptic digest of in vivo nitrated L-PGDS from non-HIV (control) and HAND CSF














AQGFTEDTIVFLPQTDK 2 54 955.5187 1,909.0228 1,908.9469 0.0759
EKFTAFCKAQGFTEDTIVFLPQTDK 3 35 955.5182 2,863.5328 2,863.4102 0.1225
KNQCETRTM*LLQPAGSLGSYSYR 3 30 873.8182 2,618.4328 2,618.2581 0.1747
SPHWGSTYSVSVVETDYDQYALLYS QGSK 2 41 1,634.174 3,266.3334 3,266.5044 –0.171
SVVAPATDGGLNLTSTFLR 2 132 960.0486 1,918.0826 1,918.016 0.0666
TM*LLQPAGSLGSYSYR 2 68 881.0337 1,760.0528 1,758.8611 1.1918
WFSAGLASNSSWLR 2 20 791.1036 1,580.1926 1,580.7736 –0.5809
HAND (n=4)
AQGFTEDTIVFLPQTDK 2 77 955.4286 1,908.8426 1,908.9469 –0.1043
EKFTAFCKAQGFTEDTIVFLPQTDK 3 42 955.4282 2,863.2628 2,863.4102 –0.1475
KNQCETRTM*LLQPAGSLGSYSYR 3 17 874.1215 2,619.3427 2,618.2581 1.0846
SPHWGSTYSVSVVETDYDQYALLYS QGSK 3 74 1,090.261 3,267.7612 3,266.5044 1.2568
SVVAPATDGGLNLTSTFLR 2 129 959.8787 1,917.7428 1,918.016 –0.2732
TMLLQPAGSLGSYSYR 2 92 872.3737 1,742.7328 1,742.8661 –0.1333
TMLLQPAGSLGSY*SYR 2 50 894.941 1,787.88 1,788.874 –0.994
WFSAGLASNSSWLR 2 20 791.4687 1,580.9228 1,580.7736 0.1493
M*: oxidized methionine; Y*: NO2-modified tyrosine
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elute within ∼1.0 min of each other. The product ion
spectrum for both forms contain relative complete series of
b- and y-ions and the difference between b5/y8 and *b5/*y8
fragment ions (asterisks (*) indicate nitrated spectrum)
represent the location of the nitrotyrosine modification
(Fig. 3c). The nitrotyrosine modification also shifts the
immonium ion of tyrosine from m/z 136.10 to m/z 181.06,
as observed in Fig. 3b. The shift in the m/z value of the
tyrosine immonium ion offers an alternative route to
distinguish nitrated peptides from non-nitrated peptides.
In Vivo Nitrotyrosine Results
Nitrotyrosine Sub-proteome of non-HIV and HAND CSF
Following albumin/IgG depletion of the pooled CSF samples,
slot blot analysis was used to determine the nitrotyrosine
content in each sample. We confirmed a higher nitrotyrosine
content in the pooled HAND CSF sample compared to the
nitrotyrosine present in the non-HIV infected CSF (Fig. 4b).
The one-dimensional silver stained images in Fig. 4a
represent the fractions from the affinity-based enrichment of
both non-HIV and HAND CSF. From tandem MS analysis
of the nitrotyrosine-modified tryptic digest products, a total
of 32 proteins were identified (Electronic Supplementary
Material, Table 1). Of the identified nitrated proteins, nine
were unique to non-HIV CSF; eight were unique to HAND
CSF; and 15 were observed in both CSF specimens. It is
possible that the unique proteins identified in the non-HIV
CSF are unique to the underlying disease state of these
individuals. Alternatively, since the CSF from HIV-infected
individuals were selected for high concentration of nitrated
proteins it is possible that these proteins may have masked
the other nitrated proteins present in low concentrations. The
Scaffold Proteome software was used to evaluate the MS/MS
data of the identified proteins from both groups and spectral
counting was used as a pseudo-quantification method to
determine differential expression of the nitrated proteins. As
illustrated in Fig. 4a, there was an increase in the number of





























































A) Normalized Ion Chromatograms
Fig. 5 LTQ-Orbitrap analysis of HAND L-PGDS tryptic peptides:
TMLLQPAGSLGSYSYR and TMLLQPAGSLGSYNO2SYR. The
base peak ion chromatograms of the MS analysis of the tryptic
digestion of HAND L-PGDS are presented in Panel A. The single ion
chromatograms at m/z 872.48 and m/z 894.94 represent the detection
of the [M+2H]+2 ion of the non-nitrated and nitrated HAND L-PGDS
peptide, respectively. The tandem MS spectra of m/z 872.48 and m/z
894.94 are in Panel B
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tandem MS spectra observed in the HAND CSF sample
when compared to the spectra detected from the non-HIV
infected CSF. This suggests that there was a higher
concentration of nitrotyrosine-modified proteins in the
HAND sample, compared to the non-HIV sample, which is
consistent with the slot blot analysis. The bar graph in
Table 2 represents the total number of peptides identified per
protein in the non-HIV and HAND samples.
In Vivo L-PGDS Analysis from non-HIV and HAND CSF
L-PGDS, also known as β-trace protein, is one of the most
abundant brain-derived proteins in human CSF and is
primarily expressed in the arachnoid membrane, leptome-
ninges, and choroid plexus [12]. In addition to expression
in the central nervous system, L-PGDS is also expressed in
male genital organs, heart, and bodily fluids (plasma,
seminal fluid, amniotic fluid, CSF, and urine) [12]. L-
PGDS catalyzes the isomerization of prostaglandin-H2, the
precursor to various prostanoids, to prostaglandin-D2 in the
presence of sulfhydryl compounds and also functions as a
transporter of small non-substrate lipophilic molecules,
including thyroid hormone, retinoic acid, retinaldehyde,
bilirubin, and biliverdin [12]. Using the Catch and
Release™ system, we were able to isolate nitrotyrosine-
modified and unmodified L-PDGS from non-HIV and
HAND CSF. The total L-PGDS and nitrotyrosine content
from each sample was determined by density analysis of the
slot blot images (Fig. 4c). The total L-PGDS content was
higher in non-HIV CSF; however the content of in vivo
nitrotyrosine-modified L-PGDS was substantially higher in
HAND compared to non-HIV. This is possibly due to the
increase in nitro-oxidative stress observed in HAND. These
findings, however, need to be confirmed in individual
samples with larger sample sizes with and without HAND.
In addition to quantitative immunoblot analysis, the
enriched L-PGDS was digested with trypsin and analyzed
by tandem MS (LTQ-Orbitrap). The peptides identified from
each group are presented in Table 3. We did not identify any
B) Tandem MS of in vivo nitrated L-PGDS Peptide
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nitrated peptides in non-HIV samples; however, the doubly
charged non-nitrated (m/z 872.44) and nitrated (m/z 894.94)
TMLLQPAGSLGSYSYR ion was identified in HAND CSF
(Fig. 5a). Tandem MS analysis of modified (Fig. 5c) and
unmodified (Fig. 5b) TMLLQPAGSLGSY(NO2)SYR
revealed the presence of the –NO2 modification at Tyr
105
(*y4-ion).
A previous study demonstrated that nitrotyrosine-modified
L-PGDS exhibited a loss of enzymatic activity [12]. In this
study L-PGDS was in vitro nitrated, which may have lead to
extensive nitration of the molecule. However, from our
current findings it appears that L-PGDS in CSF of
individuals with HAND is nitrated at Tyr105, which is
involved in transportation of small lipophilic molecules.
Tyr105 is a highly conserved residue among members of the
lipocalin family and is located in the hydrophobic aromatic
cluster of the β-sheet barrel, which is thought to function as
the ligand-binding pocket [13]. Structural studies of recom-
binant mouse L-PGDS reveal that the hydrophobic aromatic
cluster plays a major role in the stabilization of retinoic acid
[13]. Retinoic acid is an active metabolite of vitamin A and
functions as a potent regulator of gene transcription. The
stabilization of retinoic acid in the hydrophobic aromatic
cluster stems from the relatively strong Van der Waals
interactions between the isoprenoid chain and β-ionone ring
of retinoic acid and the aromatic ring of Tyr (Tyr105 and
Tyr149) and Phe (Phe34, Phe39) residues [13]. Nitration of
Tyr105 alters the physical and chemical characteristics of the
residue, including non-covalent and covalent interactions. It
has been shown that the addition of the bulky –NO2 group
reduces the pKa of the hydroxyl group of Tyr and also
introduces steric restrictions to the phenolic ring of Tyr [6].
Therefore, we suggest that nitration of Tyr105 disrupts
the stabilization of retinoic acid in the hydrophobic binding
pocket of L-PGDS. Since L-PGDS is a major component of
CSF and highly concentrated in the choroid plexus, which
forms the barrier between blood and CSF, it is thought that
L-PGDS facilitates the transport of the lipophilic small
molecules (e.g., retinoic acid) across the blood/brain barrier
[14]. Consequently, interference of the stabilization of
retinoic acid as a result of Tyr105 nitration in the
hydrophobic binding pocket of L-PGDS, could prevent
the delivery of retinoic acid to specific target tissues.
Previous studies have linked retinoid compounds to the
suppression of proinflammatory cytokine and chemokine
production during HIV-induced CNS inflammation [15].
Vitamin A deficiency has been associated with enhanced T
cell-mediated proinflammatory immune response, which
has been shown to contribute to immune-induced tissue
damage and also the progression of human disease [15]. It
is thought that the HIV infection triggers events that lead to
a reduction in plasma levels of vitamin A, which could
increase the clinical consequences of HIV infection [15].
Therefore, the inability of nitrotyrosine-modified L-
PGDS to transport retinoic acid could potentially lead to
the increased progression of the proinflammatory response
of HIV-associated neurocognitive dysfunction.
Conclusion
Utilizing immunoaffinity-based enrichment and tandem mass
spectrometry we were able to identify and characterize
nitrotyrosine-modified proteins from HAND CSF. More
specifically, we were able to isolate nitrotyrosine-modified L-
PGDS from CSF and characterize the modification site. We
conclude from previous structures of mouse L-PGDS, that
nitration of Tyr105 of L-PGDS can potentially alter its ability
to transport retinoic acid, a known regulator of gene
expression. A deficiency in vitamin A metabolites has been
shown to contribute to the proinflammatory response
observed during host invasion (e.g., HIV infection). In
addition to its ligand-binding function, L-PGDS also converts
prostaglandin-H2 into prostaglandin-D2 which is known to
play a major role in the inflammatory response, sleep, and
also vasodilation. Previous studies have observed elevated
levels of prostaglandins in individuals diagnosed with HIV-
associated neurocognitive dysfunction [16]. Therefore, fur-
ther characterization of the influence of nitration on the
function of L-PGDS in individuals diagnosed with HAND
may lead to the development of potential clinical diagnostics
or therapies for HIV-associated neurocognitive dysfunction.
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